Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
M. D. Anderson, J&J Sign Cancer Pact
by Lisa M. Jarvis
January 27, 2014
| A version of this story appeared in
Volume 92, Issue 4
Johnson & Johnson Innovation, a partnering arm of the big pharma firm’s biotech unit, has teamed up with the University of Texas M. D. Anderson Cancer Center to develop cancer immunotherapies. The partners will focus on developing combination therapies and personalized medicines and on identifying new treatments. The three-year pact is part of the medical center’s “moon shots” immunotherapy platform, which calls for multidisciplinary teams to launch six concerted attacks against eight cancers. M. D. Anderson has invested $40 million in its immunotherapy platform.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X